MONTREAL, August 3, 2026 – We are pleased to announce the expansion of our healthcare platform with the acquisition of ViOptix Inc., a manufacturer of non-invasive tissue oximetry systems used by plastic and reconstructive surgeons to monitor blood flow in transplanted tissue, most commonly in breast reconstruction following mastectomy.

Founded in 1999 and headquartered in Newark, California, ViOptix has built a trusted reputation among plastic and reconstructive surgeons, whose teams rely on its T.Ox monitors during and after some of the most delicate procedures in medicine.

Dr. Ali Youssef, Managing Director of Permanent's Healthcare Platform, commented, “Behind every T.Ox monitor is a patient recovering from breast reconstruction or another life-altering surgery. ViOptix has built a technology that clinicians rely on at the moments that matter most, and we want to deliver a product worthy of that trust.”

With this acquisition, Permanent Corp expands its healthcare platform, supporting clinicians across plastic and reconstructive surgery.

About Permanent Corp

Permanent acquires and develops market-leading niche businesses that design and manufacture mission-critical products. Permanent's long-term investment strategy allows its companies to benefit from shared best practices, a decentralized structure, and a long-term orientation. For more information, please visit Permanent Corp | Long-Term Acquirer of Niche B2B Companies